Dergiler / Üroonkoloji Bülteni / 2020 / Cilt: 19 - Sayı: 3

The Current Strategies for Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: The Place of Immunotherapy in Future

Sayfa
104–106
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this article, we aimed to review current neoadjuvant treatment strategies in muscle invasive bladder cancer in the literature.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Muscle invasion is present in approximately thirty percent of bladder cancers.
📊
Temel Bulgular & Veri:Local and distant relapses are seen in a significant proportion of patients with surgery alone.
💡
Sonuç & Katkı:In this article, we aimed to review current neoadjuvant treatment strategies in muscle invasive bladder cancer in the literature.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Muscle invasion is present in approximately thirty percent of bladder cancers. Radical cystectomy and bilateral pelvic lymph node dissection following neoadjuvant chemotherapy is the recommended treatment for muscle invasive bladder cancer. Local and distant relapses are seen in a significant proportion of patients with surgery alone. Micrometastases at the time of diagnosis that cannot be detected by imaging may be responsible for these relapses. The aim of neoadjuvant and adjuvant therapies is to eliminate these micrometastases. Several randomized trials have shown that platinum-based combination neoadjuvant chemotherapy can improve survival outcomes, compared with locoregional treatment alone. Although the proportion of patients receiving treatment has increased compared to previous years, it is still low. Immunotherapies in neoadjuvant treatment are promising in the appropriate patient group. In this article, we aimed to review current neoadjuvant treatment strategies in muscle invasive bladder cancer in the literature.

🔖

Bu Makaleye Atıf Yap

ERCELEP, Ö. (2020). The Current Strategies for Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: The Place of Immunotherapy in Future. Üroonkoloji Bülteni, Cilt: 19 - Sayı: 3, 104–106. https://ajindex.com/articles/334861

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Raghavan D, Shipley WU, Garnick MB, et al. Biology and Management of Bladder Cancer. N Engl J Med 1990;332:1129-1138.
  2. Miles BJ, Fairey AS, Eliasziw M, et al. Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Can Urol Assoc J 2010;4:263-267.
  3. Porter MP, Kerrigan MC, Donato BM, Ramsey SD. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol 2011;29:252-258.
  4. Apolo AB, Kim JW, Bochner BH, et al. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol 2014;32:637-644.
  5. Raj GV, Karavadia S, Schlomer B, et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscleinvasive bladder cancer. Cancer 2011;117:276-282.
  6. Audenet F, Sfakianos JP, Waingankar N, et al. A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging. Urol Oncol 2019;37:116-122. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361:1927-1934.
  7. Galsky MD, Pal SK, Chowdhury S, et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscleinvasive bladder cancer. Cancer 2015;121:2586-2593.
  8. Zargar H, Espiritu PN, Fairey AS, et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2015;67:241-249.
  9. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-866. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven-year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42:50-54. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001;19:2638-2646.
  10. Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dosedense methotr